Abstract: An introducer for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method of treating and angeological disease using a bifurcated stent; an endoluminal stent having perpendicular hoop members, each hoop member formed of wire in a sinuous configuration, at least some of juxtaposed apices in neighboring hoops being secured to one another, such stents also forming axially aligned segments in straight stents, and segments of bifurcated stents in particular embodiments. Certain embodiments of such stents also include barbs, fabric covering and radiopaque markers.

Abstract: An introducer for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method of treating and angiological disease using a bifurcated stent; an endoluminal stent having perpendicular hoop members, each hoop member formed of wire in a sinuous configuration, at least some of juxtaposed apices in neighboring hoops being secured to one another, such stents also forming axially aligned segments in straight stents, and segments of bifurcated stents in particular embodiments. Certain embodiments of such stents also include barbs, fabric covering and radiopaque markers.

Abstract: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment.

Abstract: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.

Abstract: Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.

Abstract: A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and other conditions that may be treated with a botulinum toxin, particularly paralysis of subcutaneous, and most particularly, facial, muscles, by topically applying an effective amount of the botulinum toxin and carrier, in conjunction, to the subject's skin or epithelium. Kits for administration are also described.

Abstract: Compositions and therapeutic methods are provided that are useful agent for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGE The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.

Abstract: A stent based drug delivery system. A biological agent of interest is entrapped within a matrix, which is loaded into channels on the surface of a stent. The matrix allows for release, usually sustained release, of the entrapped agent. The stent and matrix is sheathed with a covalently bound gel. In one embodiment of the invention, the stent is used to deliver therapeutic agents to a patient, providing the advantage of efficient delivery and sustained release of an agent at a localized site. In another embodiment of the invention, the drug delivery system is used for testing and comparison of candidate drugs in an in vivo setting.

Abstract: Restenosis is inhibited through local delivery of anti-restenotic agents including angiotensin converting enzyme inhibitors; nicotine receptor agonists, agents that increase concentrations of nitric oxide, anti-angiogenic agents, agonists of the TGF-beta receptor; death domain receptor ligands; and thrombin inhibitors. In one embodiment of the invention, the localized delivery is effected through the use of a stent modified for delivery of the agent at the site of injury from balloon angioplasty.

Abstract: The invention comprises:

Abstract: Methods of altering properties of tissues, by providing an effective modifying amount of zinc, which may be in the form of zinc ions. This is accomplished through the use of topical compositions containing one or more zinc-containing components such as salts and/or other zinc compounds or complexes, particularly zinc acetate.

Abstract: Implantable medical devices using zinc, and methods therefore, provide one or more advantageous effects to a tissue. In one embodiment, at least one zinc-containing component is coupled with a stent via one or more zinc chelators to enhance resistance of the stent to plaque formation and in-stent restenosis. Elastin production may also be enhanced by devices coupled with zinc. Enhanced elastin production may be used, for example, to treat a blood vessel in location at or near an aneurysm. In some embodiments, both elastin production and plaque resistance are enhanced. For example, zinc may be applied via a gel or other carrier substance to a venous graft for enhancing elastin and resisting plaque formation. Implantable devices coupled with zinc may provide improved results of medical and surgical procedures involving implantable devices, thus reducing the need for repeat procedures.

Abstract: An introducer for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method of treating and angeological disease using a bifurcated stent; an endoluminal stent having perpendicular hoop members, each hoop member formed of wire in a sinuous configuration, at least some of juxtaposed apices in neighboring hoops being secured to one another, such stents also forming axially aligned segments in straight stents, and segments of bifurcated stents in particular embodiments. Certain embodiments of such stents also include barbs, fabric covering and radiopaque markers.

Abstract: The invention comprises:

Abstract: An introducer for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method for delivering into the vasculature a straight or bifurcated stent or prosthesis; a method of treating and angeological disease using a bifurcated stent; an endoluminal stent having perpendicular hoop members, each hoop member formed of wire in a sinuous configuration, at least some of juxtaposed apices in neighboring hoops being secured to one another, such stents also forming axially aligned segments in straight stents, and segments of bifurcated stents in particular embodiments. Certain embodiments of such stents also include barbs, fabric covering and radiopaque markers.

Abstract: The invention comprises:

Abstract: Compositions of matter comprise linked pluralities of mTOR-binding molecules, such as rapamycin. The compositions may be directly polymerized or may comprise rapamycin or other mTOR-binding molecules covalently or non-covalently attached to a backbone molecule. The compositions may be bound to vascular prostheses and other implantable devices in order to inhibit hyperplasia or for other therapeutic purposes.

Abstract: A stent based drug delivery system. A biological agent of interest is entrapped within a matrix, which is loaded into channels on the surface of a stent. The matrix allows for release, usually sustained release, of the entrapped agent. The stent and matrix is sheathed with a covalently bound gel. In one embodiment of the invention, the stent is used to deliver therapeutic agents to a patient, providing the advantage of efficient delivery and sustained release of an agent at a localized site. In another embodiment of the invention, the drug delivery system is used for testing and comparison of candidate drugs in an in vivo setting.

Abstract: Restenosis is inhibited through local delivery of anti-restenotic agents including angiotensin converting enzyme inhibitors; nicotine receptor agonists, agents that increase concentrations of nitric oxide, anti-angiogenic agents, agonists of the TGF-beta receptor; death domain receptor ligands; and thrombin inhibitors. In one embodiment of the invention, the localized delivery is effected through the use of a stent modified for delivery of the agent at the site of injury from balloon angioplasty.

Abstract: A delivery catheter having an inner catheter assembly, an inferior capsule catheter, and a capsule jacket assembly for use in deploying a graft having a compressible and expandable attachment systems in the thoracic region of an aorta. The graft is comprised of a tubular member having superior and inferior ends, each having an attachment system with wall engaging members secured thereto and is crimped along its midsection to resist kinking and elongation. The delivery catheter includes an inferior capsule assembly for releasably retaining the inferior attachment system of the graft and a superior capsule assembly for releasably retaining the superior attachment system of the graft as well as a releasing system for maintaining the attachment systems in a compressed configuration and for facilitating expansion of the attachment systems.